We're looking for participants for our UX research study. Share your thoughts and help shape the future of our product. Sign up today and make an impact!
The agreement provides Open Access publishing in Core Hybrid, Cell Press and The Lancet titles and Read Access to existing ScienceDirect and Cell Press Journals. It also provides a discount on OA publishing in Elsevier's portfolio of fully open access titles.
The transitional offer provides unlimited open access publishing to UK authors in Elsevier's hybrid journals including the Cell Press and Lancet titles and delivers a 15% reduction on contracted and direct subscription expenditure with Elsevier.
The fully gold proposal is entirely opt in and provides a 15% reduction on all article processing charges (APCs), flexible payment options and a price cap on annual increases to APCs paid by UK institutions. Please contact Elsevier to opt into the full gold proposal.
For read access, the proposal takes each institution's current subscriptions and applies the reduction to this amount; it does not extend read access rights. Read access is provided to all titles within the collection subscribed to by an institution in that subscription year.
For example, a Freedom Collection subscriber would continue to access all Freedom Collection titles (inclusive of the Cell Press and Lancet titles that currently sit within the Freedom Collection) for the lifetime of the agreement. For any titles that sit outside the Freedom Collection for which the institution does not subscribe to, the institution will have the option to publish OA but not read. Archive rights will be retained to all subscribed titles.
Please find the Workflow documents here in the secure filestore:
If you do not have access, please email licensing@jisc.ac.uk
Agreement extended for one year in 2025 as provided by the contract and agreed by the sector in the June 2024 consultation.
The transitional offer provides unlimited open access publishing to UK authors in Elsevier's Core hybrid journals, Cell Press and The Lancet journals and delivers a 15% reduction on contracted and direct subscription expenditure with Elsevier.
The fully gold open access journals proposal is entirely opt in and provides a 15% reduction on all APCs, flexible payment options and a price cap on APCs paid by UK institutions.
For read access, the proposal takes each institution's current contracted subscriptions and applies the reduction to this amount; it does not extend read access rights. Institutions have received their quotations via the secure area. Read access is provided to all titles within the collection subscribed to by an institution in that subscription year.
For example, a Freedom Collection subscriber would continue to access all Freedom Collection titles (inclusive of the Cell Press and Lancet titles that currently sit within the Freedom Collection) for the lifetime of the agreement. For any titles that sit outside the Freedom Collection for which the institution does not subscribe to, the institution will have the option to publish OA3 but not read. Archive rights will be retained to all subscribed titles.
The fully open access offer provides the following:
15% discount on list price APCs across all fully OA titles including Core gold, Cell Press and The Lancet
2.7% cap on APC annual increases where title is five years +. For titles younger than five years no APC cap applicable, given the immature nature of APC pricing and introductory discounts and offers already in place
Subscription (hybrid) titles that "flip" to OA over the lifetime of the agreement will continue to be treated as hybrid and benefit from OA publishing
Payment flexibility - each institution may opt for one of the following payment options:
While possible to accommodate all three options, this is administratively complex, and Elsevier has requested that changes to schemes are not made during the agreement.
On payment of the Content Fee, Institutions shall have access to the full-text of all articles from Subscribed Titles published and paid for during the respective subscription year of this Agreement and previous licences from the beginning of the year the subscription started, plus, without additional charge, the full-text of all articles from Subscribed Titles published during the four (4) years previous to the year in which the subscription commenced.
On payment of the Content Fee Institutions which entered into an IDEAL licence for the 1993 subscription year shall have for each subscription year without any additional charge electronic access via ScienceDirect to twenty five (25) calendar years (building from 1 January 2017 plus a backfile of the twenty (20) previous years back to 1 January 1993) of full text of all articles from the journal titles subscribed to and accessible electronically from the IDEAL® platform prior to the beginning of 2017 and previous licences. The same principle (access from the beginning of the term of a previous licence for IDEAL plus a backfile of accrued backfile years without any additional charge) shall apply to Institutions that entered into new or extended their previous licence for IDEAL to subscription years after 1993.
The Content Fee shall also include (without any additional charge) electronic access to any cancelled journal titles in ScienceDirect subscribed to and paid for by an Institution during the subscription period of the current licence (covering the 2017-2021 subscription years) and during the subscription periods of previous licences.
Institutions shall also have access to the full-text of non-subscribed titles.
Information not available.
Information not available.
Elsevier Accessibility Information
Elsevier support all major SSO methods.
No
Yes
There is an Elsevier DTD spec for journal articles and another for book chapters. This is XML based and - in principle - can be re-cut into various formats. We make metadata records available in a standardized way through the KBART process (KnowledgeBase Automation and Retrieval Technologies).
Yes.
Post search options offered e.g. saved searches. Search History and Reading History are available for signed in users.
Boolean operators currently supported include AND, OR, NOT, and the hyphen (or minus symbol).
Boolean operators must be entered in all uppercase.
The hyphen (or minus symbol) is interpreted as the NOT operator.
Example: black -hole will return results containing 'black', but exclude any instances where 'hole' appears with it.
Boolean precedence is as follows:
NOT
AND
OR
Parentheses can be used when nesting clauses so the grouping is clear and unambiguous.
Example: Instead of searching a. OR b. AND c. OR d.
Please use (a OR b) AND (c OR d)
Quotation marks can be used to specify terms which must appear next to each other.
Example: ("heart attack" OR "myocardial infarction") AND diabetes AND NOT cancer.
The above example can be expressed more concisely as: ("heart attack" OR "myocardial infarction") diabetes - cancer.
Rules
Punctuation is ignored in a phrase search. The searches "heart-attack" and "heart attack" return the same results.
Plurals and spelling variants are included: "heart attack" includes "heart attacks", "color code" includes "colour code."
ScienceDirect supports the UTF-8 character set, meaning you can enter all UTF-8 characters directly in the search form, including non-Roman and accented characters.
After completing your search, you can use the filters available on the Search results page to refine your results by: